{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:48:31Z","timestamp":1771919311778,"version":"3.50.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004733","name":"Universidade de Macau","doi-asserted-by":"publisher","award":["MYRG2020-00230-ICMS"],"award-info":[{"award-number":["MYRG2020-00230-ICMS"]}],"id":[{"id":"10.13039\/501100004733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hepatocellular carcinoma (HCC) is one of the cancers with the highest morbidity and mortality. Sorafenib used to be the main treatment for unresectable HCC patients. However, regimens based on immune checkpoint inhibitors (ICIs) have attracted attention in recent years because of their reported benefits. This study aimed to evaluate the efficacy and safety of monotherapy and combination therapy of ICIs as first-line treatment for unresectable HCC patients by conducting a systematic review, meta-analysis, and network meta-analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Studies published up to 11st August 2022 were searched from 4 commonly used databases, including PubMed, Web of Science, Embase, and Clinical trials.gov. All eligible clinical trials were included. Data about reported objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and treatment-related adverse events (TRAEs) were extracted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 8579 studies retrieved, 24 met the inclusion criteria. In patients with unresectable HCC taking ICIs-based therapy as first-line treatment, the pooled result of median PFS and median OS was 5.76\u00a0months (95% CI 4.82\u20136.69) and 16.35\u00a0months (95% CI 15.19\u201317.51) The ORR and DCR were 25.1% (95% CI 20.8\u201329.5%) and 75.2% (95% CI 70.3\u201380.2%) measured by RECIST v1.1 or 40.2% (95% CI 31.7\u201348.6%) with 75.2% (95% CI 68.3\u201382.1%) measured by mRECIST v1.1. Compared to sorafenib, ICIs-based therapy significantly prolonged OS. The combination treatment of sintilimab plus IBI305 had the highest ORR, while atezolizumab plus bevacizumab had the highest DCR. The pooled incidence of any grade TRAEs was 82.3% (95% CI 73.9\u201390.7%), with highest incidence appeared in dysphonia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study demonstrated that first-line ICIs-based therapies could provide survival benefits for patients with unresectable HCC, with manageable TRAEs. The potential of combination treatment to become the new treatment trend in clinical practice is promising.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12672-022-00559-1","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T16:05:25Z","timestamp":1664381125000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis"],"prefix":"10.1007","volume":"13","author":[{"given":"Qing","family":"Lei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfeng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina Oi Lam","family":"Ung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"issue":"3","key":"559_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"559_CR2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","volume":"161","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Ferlay J, de Martel C, Georges D, Ibrahim AS, Zheng R, Wei W, Lemmens V, Soerjomataram I. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer. 2022;161:108\u201318.","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"559_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","volume":"73","author":"KA McGlynn","year":"2021","unstructured":"McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(Suppl 1):4\u201313.","journal-title":"Hepatology"},{"issue":"3","key":"559_CR4","doi-asserted-by":"publisher","first-page":"107327481772924","DOI":"10.1177\/1073274817729245","volume":"24","author":"NN Massarweh","year":"2017","unstructured":"Massarweh NN, El-Serag HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control. 2017;24(3):1073274817729245.","journal-title":"Cancer Control"},{"issue":"5","key":"559_CR5","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.bpg.2014.08.007","volume":"28","author":"C Bosetti","year":"2014","unstructured":"Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol. 2014;28(5):753\u201370.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"15","key":"559_CR6","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.3748\/wjg.v20.i15.4115","volume":"20","author":"A Raza","year":"2014","unstructured":"Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol. 2014;20(15):4115\u201327.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"559_CR7","doi-asserted-by":"publisher","first-page":"673","DOI":"10.4254\/wjh.v7.i4.673","volume":"7","author":"AI Gomaa","year":"2015","unstructured":"Gomaa AI, Waked I. Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol. 2015;7(4):673\u201387.","journal-title":"World J Hepatol"},{"issue":"1","key":"559_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s15010-019-01345-y","volume":"48","author":"E Sagnelli","year":"2020","unstructured":"Sagnelli E, Macera M, Russo A, Coppola N, Sagnelli C. Epidemiological and etiological variations in hepatocellular carcinoma. Infection. 2020;48(1):7\u201317.","journal-title":"Infection"},{"issue":"4","key":"559_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"559_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110797","volume":"132","author":"Y Wang","year":"2020","unstructured":"Wang Y, Jiang M, Zhu J, Qu J, Qin K, Zhao D, Wang L, Dong L, Zhang X. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma. Biomed Pharmacother. 2020;132: 110797.","journal-title":"Biomed Pharmacother"},{"issue":"10088","key":"559_CR11","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling THR, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492\u2013502.","journal-title":"Lancet"},{"issue":"7","key":"559_CR12","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940\u201352.","journal-title":"Lancet Oncol"},{"issue":"20","key":"559_CR13","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"key":"559_CR14","unstructured":"Hepatobiliary Cancers (Version 5.2021) [https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1438]"},{"issue":"3","key":"559_CR15","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.annonc.2019.12.001","volume":"31","author":"LT Chen","year":"2020","unstructured":"Chen LT, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS, Ikeda M, Lim HY, Ho GF, Choo SP, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced\/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020;31(3):334\u201351.","journal-title":"Ann Oncol"},{"key":"559_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.626984","volume":"11","author":"S He","year":"2021","unstructured":"He S, Jiang W, Fan K, Wang X. The efficacy and safety of programmed death-1 and programmed death ligand 1 inhibitors for the treatment of hepatocellular carcinoma: a systematic review and meta-analysis. Front Oncol. 2021;11: 626984.","journal-title":"Front Oncol"},{"issue":"6","key":"559_CR17","doi-asserted-by":"publisher","first-page":"e1036","DOI":"10.1002\/onco.13638","volume":"26","author":"IA Ziogas","year":"2021","unstructured":"Ziogas IA, Evangeliou AP, Giannis D, Hayat MH, Mylonas KS, Tohme S, Geller DA, Elias N, Goyal L, Tsoulfas G. The role of immunotherapy in hepatocellular carcinoma: a systematic review and pooled analysis of 2,402 patients. Oncologist. 2021;26(6):e1036\u201349.","journal-title":"Oncologist"},{"issue":"6","key":"559_CR18","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.hbpd.2019.09.007","volume":"18","author":"IA Voutsadakis","year":"2019","unstructured":"Voutsadakis IA. PD-1 inhibitors monotherapy in hepatocellular carcinoma: meta-analysis and systematic review. Hepatobiliary Pancreat Dis Int. 2019;18(6):505\u201310.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"3","key":"559_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1159\/000515302","volume":"10","author":"A Vogel","year":"2021","unstructured":"Vogel A, Rimassa L, Sun HC, Abou-Alfa GK, El-Khoueiry A, Pinato DJ, Sanchez Alvarez J, Daigl M, Orfanos P, Leibfried M, et al. Comparative efficacy of atezolizumab plus bevacizumab and other treatment options for patients with unresectable hepatocellular carcinoma: a network meta-analysis. Liver Cancer. 2021;10(3):240\u20138.","journal-title":"Liver Cancer"},{"issue":"5","key":"559_CR20","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s12072-020-10064-8","volume":"14","author":"Q Rao","year":"2020","unstructured":"Rao Q, Li M, Xu W, Pang K, Guo X, Wang D, Liu J, Guo W, Zhang Z. Clinical benefits of PD-1\/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int. 2020;14(5):765\u201375.","journal-title":"Hepatol Int"},{"issue":"11","key":"559_CR21","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"issue":"2","key":"559_CR22","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.recesp.2021.10.020","volume":"75","author":"MJ Page","year":"2022","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews (74, pg 790, 2021). Rev Esp Cardiol. 2022;75(2):192\u2013192.","journal-title":"Rev Esp Cardiol"},{"key":"559_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-014-0579-0","author":"AM Methley","year":"2014","unstructured":"Methley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S. PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. Bmc Health Serv Res. 2014;14(1):1\u201310.","journal-title":"Bmc Health Serv Res"},{"key":"559_CR24","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JAC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed). 2011;343:d5928\u2013d5928.","journal-title":"BMJ (Clinical research ed)"},{"key":"559_CR25","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford; 2000."},{"key":"559_CR26","doi-asserted-by":"crossref","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153\u2013160.","DOI":"10.1136\/ebmental-2019-300117"},{"key":"559_CR27","doi-asserted-by":"crossref","unstructured":"R\u00fccker G. Network meta\u2010analysis, electrical networks and graph theory. Res Synth Methods. 2012;3(4):312\u2013324.","DOI":"10.1002\/jrsm.1058"},{"key":"559_CR28","doi-asserted-by":"publisher","first-page":"e2019013","DOI":"10.4178\/epih.e2019013","volume":"41","author":"SR Shim","year":"2019","unstructured":"Shim SR, Kim S-J, Lee J, R\u00fccker G. Network meta-analysis: application and practice using R software. Epidemiol Health. 2019;41:e2019013\u2013e2019013.","journal-title":"Epidemiol Health"},{"key":"559_CR29","doi-asserted-by":"crossref","unstructured":"Butts CT. network: a Package for Managing Relational Data in R. J Stat Softw. 2008;24:1\u201336.","DOI":"10.18637\/jss.v024.i02"},{"issue":"1","key":"559_CR30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G R\u00fccker","year":"2015","unstructured":"R\u00fccker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15(1):58.","journal-title":"BMC Med Res Methodol"},{"issue":"7109","key":"559_CR31","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"3","key":"559_CR32","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jhep.2021.04.047","volume":"75","author":"M Kudo","year":"2021","unstructured":"Kudo M, Matilla A, Santoro A, Melero I, Graci\u00e1n AC, Acosta-Rivera M, Choo SP, El-Khoueiry AB, Kuromatsu R, El-Rayes B, et al. CheckMate 040 cohort 5: a phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. J Hepatol. 2021;75(3):600\u20139.","journal-title":"J Hepatol"},{"key":"559_CR33","doi-asserted-by":"publisher","first-page":"v874","DOI":"10.1093\/annonc\/mdz394.029","volume":"30","author":"T Yau","year":"2019","unstructured":"Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Han KH, Harding JJ, Merle P, et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;30:v874\u20135.","journal-title":"Ann Oncol"},{"issue":"12","key":"559_CR34","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1158\/1078-0432.CCR-21-3807","volume":"28","author":"G Verset","year":"2022","unstructured":"Verset G, Borbath I, Karwal M, Verslype C, Van Vlierberghe H, Kardosh A, Zagonel V, Stal P, Sarker D, Palmer DH, et al. Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: data from the open-label, phase II KEYNOTE-224 trial. Clin Cancer Res. 2022;28(12):2547\u201354.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"559_CR35","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/S1470-2045(20)30156-X","volume":"21","author":"MS Lee","year":"2020","unstructured":"Lee MS, Ryoo BY, Hsu CH, Numata K, Stein S, Verret W, Hack SP, Spahn J, Liu B, Abdullah H, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21(6):808\u201320.","journal-title":"Lancet Oncol"},{"issue":"7","key":"559_CR36","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol. 2021;22(7):977\u201390.","journal-title":"Lancet Oncol"},{"issue":"4_suppl","key":"559_CR37","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1200\/JCO.2022.40.4_suppl.435","volume":"40","author":"C Hao","year":"2022","unstructured":"Hao C, Du C, Peng B, Zhang W, Shan Y, Lv A, Wu J, Shang C, Luo X, Wei J, et al. Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: a single-arm phase II study. J Clin Oncol. 2022;40(4_suppl):435\u2013435.","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"559_CR38","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1200\/JCO.2022.40.4_suppl.434","volume":"40","author":"T Meyer","year":"2022","unstructured":"Meyer T, Ledin E, Kim D-W, Ghiringhelli F, Serwatowski P, Voskoboynik M, Landsteiner HT, Chen V, Jayadeva G, Macarulla T. Phase Ib study of BI 836880 (VEGF\/Ang2 inhibitor) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2022;40(4_suppl):434\u2013434.","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"559_CR39","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1200\/JCO.2022.40.4_suppl.436","volume":"40","author":"HY Lim","year":"2022","unstructured":"Lim HY, Heo J, Kim T-Y, Tai WMD, Kang Y-K, Lau G, Kudo M, Tak WY, Watras M, Ali SK, et al. Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: results from the phase 2 study 22 (NCT02519348). J Clin Oncol. 2022;40(4_suppl):436\u2013436.","journal-title":"J Clin Oncol"},{"issue":"7","key":"559_CR40","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/hepr.13771","volume":"52","author":"K Maesaka","year":"2022","unstructured":"Maesaka K, Sakamori R, Yamada R, Doi A, Tahata Y, Miyazaki M, Ohkawa K, Mita E, Iio S, Nozaki Y, et al. Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma. Hepatol Res. 2022;52(7):630\u201340.","journal-title":"Hepatol Res"},{"issue":"26","key":"559_CR41","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960\u201370.","journal-title":"J Clin Oncol"},{"issue":"4","key":"559_CR42","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","volume":"27","author":"J Xu","year":"2021","unstructured":"Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J, Shao G, Zhang Y, Xu L, Yin T, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label Phase II Trial. Clin Cancer Res. 2021;27(4):1003\u201311.","journal-title":"Clin Cancer Res"},{"issue":"3_suppl","key":"559_CR43","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1200\/JCO.2021.39.3_suppl.323","volume":"39","author":"RD Kim","year":"2021","unstructured":"Kim RD, Harris WP, Sung MW, Waldschmidt DT, Cabrera R, Mueller U, Menezes F, Ishida T, Galle PR, El-Khoueiry AB. Results of a phase Ib study of regorafenib (REG) 80 mg\/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2021;39(3_suppl):323\u2013323.","journal-title":"J Clin Oncol"},{"issue":"3_suppl","key":"559_CR44","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1200\/JCO.2021.39.3_suppl.306","volume":"39","author":"SC Jiao","year":"2021","unstructured":"Jiao SC, Bai LI, Dong J, Bai C, Hu C, Shen L, Qin Q, Bai Y, Fan J, Zang A, et al. Penpulimab (Anti-PD-1) combined with anlotinib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): updated results from a phase Ib\/II study. J Clin Oncol. 2021;39(3_suppl):306\u2013306.","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"559_CR45","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1200\/JCO.2020.38.4_suppl.513","volume":"38","author":"M Kudo","year":"2020","unstructured":"Kudo M, Ikeda M, Motomura K, Okusaka T, Kato N, Dutcus CE, Hisai T, Suzuki M, Ikezawa H, Iwata T, et al. A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117. J Clin Oncol. 2020;38(4_suppl):513\u2013513.","journal-title":"J Clin Oncol"},{"issue":"3","key":"559_CR46","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000514420","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo M, Motomura K, Wada Y, Inaba Y, Sakamoto Y, Kurosaki M, Umeyama Y, Kamei Y, Yoshimitsu J, Fujii Y, et al. Avelumab in combination with axitinib as first-line treatment in patients with advanced hepatocellular carcinoma: results from the phase 1b VEGF liver 100 trial. Liver Cancer. 2021;10(3):249\u201359.","journal-title":"Liver Cancer"},{"issue":"3_suppl","key":"559_CR47","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1200\/JCO.2021.39.3_suppl.314","volume":"39","author":"H Lin","year":"2021","unstructured":"Lin H, Ma J, Zhuo M, Zhang C, Luo J, Zhuang X, Zeng Z, Yang L. Preliminary results of the phase II ALTER-H003 trial: anlotinib plus toripalimab as a first-line treatment for patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2021;39(3_suppl):314\u2013314.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"559_CR48","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1200\/JCO.2021.39.15_suppl.4101","volume":"39","author":"L Bai","year":"2021","unstructured":"Bai L, Sun M, Xu A, Bai Y, Wu J, Shao G, Song L, Jin X, Song W, Li B, et al. Phase 2 study of AK104 (PD-1\/CTLA-4 bispecific antibody) plus lenvatinib as first-line treatment of unresectable hepatocellular carcinoma. J Clin Oncol. 2021;39(15_suppl):4101\u20134101.","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"559_CR49","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.2022.40.4_suppl.415","volume":"40","author":"C Yoo","year":"2022","unstructured":"Yoo C, Ryoo B-Y, Kim H-D, Ryu M-H, Kang B, Chon HJ, Hong JY, Lim HY. Regorafenib plus nivolumab as first-line therapy for unresectable hepatocellular carcinoma (uHCC): multicenter phase 2 trial (RENOBATE). J Clin Oncol. 2022;40(4_suppl):415\u2013415.","journal-title":"J Clin Oncol"},{"issue":"8","key":"559_CR50","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","volume":"23","author":"RK Kelley","year":"2022","unstructured":"Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(8):995\u20131008.","journal-title":"Lancet Oncol"},{"key":"559_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.909035","volume":"12","author":"X Chen","year":"2022","unstructured":"Chen X, Li W, Wu X, Zhao F, Wang D, Wu H, Gu Y, Li X, Qian X, Hu J, et al. Safety and efficacy of sintilimab and anlotinib as first line treatment for advanced hepatocellular carcinoma (KEEP-G04): a single-arm phase 2 study. Front Oncol. 2022;12: 909035.","journal-title":"Front Oncol"},{"key":"559_CR52","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2147\/DDDT.S304857","volume":"15","author":"H Li","year":"2021","unstructured":"Li H, Qin S, Liu Y, Chen Z, Ren Z, Xiong J, Meng Z, Zhang X, Wang L, Zhang X, et al. Camrelizumab combined with FOLFOX4 regimen as first-line therapy for advanced hepatocellular carcinomas: a sub-cohort of a multicenter phase Ib\/II study. Drug Des Devel Ther. 2021;15:1873\u201382.","journal-title":"Drug Des Devel Ther"},{"issue":"15_suppl","key":"559_CR53","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1200\/JCO.2021.39.15_suppl.4083","volume":"39","author":"M He","year":"2021","unstructured":"He M, Ming S, Lai Z, Li Q. A phase II trial of lenvatinib plus toripalimab and hepatic arterial infusion chemotherapy as a first-line treatment for advanced hepatocellular carcinoma (LTHAIC study). J Clin Oncol. 2021;39(15_suppl):4083\u20134083.","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"559_CR54","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1200\/JCO.2022.40.4_suppl.379","volume":"40","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Chan SL, Kudo M, Lau G, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang Y-K, Dao TV, De Toni EN, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol. 2022;40(4_suppl):379\u2013379.","journal-title":"J Clin Oncol"},{"issue":"4","key":"559_CR55","first-page":"2379","volume":"13","author":"A Facciorusso","year":"2021","unstructured":"Facciorusso A, Tartaglia N, Villani R, Serviddio G, Ramai D, Mohan BP, Chandan S, Abd El Aziz MA, Evangelista J, Cotsoglou C, et al. Lenvatinib versus sorafenib as first-line therapy of advanced hepatocellular carcinoma: a systematic review and meta-analysis. Am J Transl Res. 2021;13(4):2379.","journal-title":"Am J Transl Res."},{"issue":"11","key":"559_CR56","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1080\/17474124.2021.1973431","volume":"15","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Ricci AD, Gadaleta-Caldarola G, Brandi G. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. Expert Rev Gastroenterol Hepatol. 2021;15(11):1245\u201351.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"559_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.898964","author":"C Donisi","year":"2021","unstructured":"Donisi C, Puzzoni M, Ziranu P, Lai E, Mariani S, Saba G, Impera V, Dubois M, Persano M, Migliari M, et al. Immune checkpoint inhibitors in the treatment of HCC. Front Oncol. 2021;10:601240.","journal-title":"Front Oncol"},{"issue":"3","key":"559_CR58","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/antib9030034","volume":"9","author":"D Zahavi","year":"2020","unstructured":"Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies. 2020;9(3):34.","journal-title":"Antibodies"},{"key":"559_CR59","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2021.12540","author":"JT Wang","year":"2021","unstructured":"Wang JT, Li J, Tang GJ, Tian Y, Su S, Li YL. Clinical outcomes and influencing factors of PD-1\/PD-L1 in hepatocellular carcinoma. Oncol Lett. 2021;21(4):1\u20131.","journal-title":"Oncol Lett"},{"issue":"1","key":"559_CR60","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/s41598-018-28337-6","volume":"8","author":"S De Lorenzo","year":"2018","unstructured":"De Lorenzo S, Tovoli F, Barbera MA, Garuti F, Palloni A, Frega G, Garajova I, Rizzo A, Trevisani F, Brandi G. Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept. Sci Rep. 2018;8(1):997.","journal-title":"Sci Rep"},{"issue":"32","key":"559_CR61","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.2217\/fon-2020-0669","volume":"16","author":"A Rizzo","year":"2020","unstructured":"Rizzo A, Ricci AD, Brandi G. Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing. Future Oncol. 2020;16(32):2587\u20139.","journal-title":"Future Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-022-00559-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-022-00559-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-022-00559-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T16:39:37Z","timestamp":1664383177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-022-00559-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["559"],"URL":"https:\/\/doi.org\/10.1007\/s12672-022-00559-1","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]},"assertion":[{"value":"10 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the content and submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}